Fidelity Investments’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,933
| Closed | -$8.76K | – | 5413 |
|
|
2025
Q3 | $8.76K | Sell |
1,933
-391
| -17% | -$1.15K | ﹤0.01% | 4644 |
|
|
2025
Q2 | $5K | Sell |
2,324
-11,146
| -83% | -$31.2K | ﹤0.01% | 4709 |
|
|
2025
Q1 | $58.9K | Sell |
13,470
-44,433
| -77% | -$200K | ﹤0.01% | 3787 |
|
|
2024
Q4 | $270K | Sell |
57,903
-176,815
| -75% | -$1.19M | ﹤0.01% | 3155 |
|
|
2024
Q3 | $1.65M | Sell |
234,718
-402,791
| -63% | -$2.92M | ﹤0.01% | 2457 |
|
|
2024
Q2 | $4.37M | Sell |
637,509
-263,018
| -29% | -$2.45M | ﹤0.01% | 2113 |
|
|
2024
Q1 | $12.7M | Buy |
900,527
+288,100
| +47% | +$4.38M | ﹤0.01% | 1803 |
|
|
2023
Q4 | $4.61M | Sell |
612,427
-56,766
| -8% | -$518K | ﹤0.01% | 2090 |
|
|
2023
Q3 | $10M | Sell |
669,193
-106,936
| -14% | -$1.92M | ﹤0.01% | 1823 |
|
|
2023
Q2 | $12.3M | Sell |
776,129
-853
| -0.1% | -$8.97K | ﹤0.01% | 1795 |
|
|
2023
Q1 | $5.57M | Sell |
776,982
-305
| -0% | -$2.16K | ﹤0.01% | 2058 |
|
|
2022
Q4 | $4.5M | Sell |
777,287
-309,578
| -28% | -$2.35M | ﹤0.01% | 2149 |
|
|
2022
Q3 | $10.3M | Sell |
1,086,865
-62
| -0% | -$815 | ﹤0.01% | 1881 |
|
|
2022
Q2 | $13M | Sell |
1,086,927
-458
| -0% | -$4.8K | ﹤0.01% | 1840 |
|
|
2022
Q1 | $14.2M | Buy |
1,087,385
+1,087,268
| +929,289% | +$15.9M | ﹤0.01% | 1958 |
|
|
2021
Q4 | $2K | Hold |
117
| – | – | ﹤0.01% | 3977 |
|
|
2021
Q3 | $3K | Hold |
117
| – | – | ﹤0.01% | 3889 |
|
|
2021
Q2 | $4K | Sell |
117
-77,327
| -100% | -$4.17M | ﹤0.01% | 3750 |
|
|
2021
Q1 | $7.64M | Hold |
77,444
| – | – | ﹤0.01% | 2136 |
|
|
2020
Q4 | $8.39M | Hold |
77,444
| – | – | ﹤0.01% | 2024 |
|
|
2020
Q3 | $7.98M | Buy |
77,444
+47,830
| +162% | +$7.16M | ﹤0.01% | 1902 |
|
|
2020
Q2 | $6.18M | Buy |
29,614
+12,113
| +69% | +$2.15M | ﹤0.01% | 1981 |
|
|
2020
Q1 | $1.71M | Buy |
+17,501
| New | +$2.04M | ﹤0.01% | 2230 |
|
|
2018
Q4 | – | Sell |
-74,082
| Closed | -$4.48M | – | 3489 |
|
|
2018
Q3 | $4.48M | Sell |
74,082
-33,668
| -31% | -$1.89M | ﹤0.01% | 2194 |
|
|
2018
Q2 | $5.71M | Buy |
107,750
+8,422
| +8% | +$506K | ﹤0.01% | 2108 |
|
|
2018
Q1 | $5.76M | Buy |
99,328
+44,319
| +81% | +$2.76M | ﹤0.01% | 2118 |
|
|
2017
Q4 | $1.93M | Sell |
55,009
-102,220
| -65% | -$3.36M | ﹤0.01% | 2355 |
|
|
2017
Q3 | $5.74M | Sell |
157,229
-23,580
| -13% | -$654K | ﹤0.01% | 2120 |
|
|
2017
Q2 | $4.52M | Sell |
180,809
-96,246
| -35% | -$2.63M | ﹤0.01% | 2193 |
|
|
2017
Q1 | $7.48M | Sell |
277,055
-93,585
| -25% | -$2.66M | ﹤0.01% | 2066 |
|
|
2016
Q4 | $10.7M | Sell |
370,640
-6,845
| -2% | -$224K | ﹤0.01% | 1938 |
|
|
2016
Q3 | $15.5M | Sell |
377,485
-9,030
| -2% | -$343K | ﹤0.01% | 1802 |
|
|
2016
Q2 | $12.2M | Buy |
386,515
+1,228
| +0.3% | +$55.5K | ﹤0.01% | 1877 |
|
|
2016
Q1 | $19.9M | Sell |
385,287
-613
| -0.2% | -$34.2K | ﹤0.01% | 1663 |
|
|
2015
Q4 | $36.7M | Buy |
385,900
+1,252
| +0.3% | +$110K | ﹤0.01% | 1380 |
|
|
2015
Q3 | $31.7M | Buy |
384,648
+2,204
| +0.6% | +$282K | ﹤0.01% | 1455 |
|
|
2015
Q2 | $62.1M | Buy |
382,444
+15,416
| +4% | +$5.2M | 0.01% | 1246 |
|
|
2015
Q1 | $149M | Buy |
367,028
+30,103
| +9% | +$12.7M | 0.02% | 839 |
|
|
2014
Q4 | $182M | Buy |
336,925
+3,196
| +1% | +$1.23M | 0.02% | 727 |
|
|
2014
Q3 | $114M | Buy |
+333,729
| New | +$99.3M | 0.02% | 910 |
|
Fidelity Investments's ADVM Position: Q4 2025 in Review
Fidelity Investments sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 1,933 shares — an estimated $8.76K sold.
Fidelity Investments first reported a position in ADVM in Q3 2014 and held it in 40 quarters. The position peaked at $182M in Q4 2014. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Fidelity Investments reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Fidelity Investments sold 1,933 Adverum Biotechnologies shares in Q4 2025, an estimated $8.76K.
- Fidelity Investments first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 40 quarters.
- Fidelity Investments's Adverum Biotechnologies position peaked at $182M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.